(Q38221015)

31 August 2017

title

Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? (English)

1 reference

31 August 2017

3

Maciej Banach

1 reference

31 August 2017

Simona Dragan

1

1 reference

31 August 2017

Maria-Corina Serban

series ordinal

2

1 reference

31 August 2017

publication date

17 June 2014

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

31 August 2017

published in

1 reference

31 August 2017

volume

20

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

157-168

1 reference

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Lipids, blood pressure, kidney - what was new in 2011?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Lipid-lowering therapies and achievement of LDL-cholesterol targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Are we getting to lipid targets in real life?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Dual regulation of the LDL receptor--some clarity and new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A new method for measurement of total plasma PCSK9: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The physiological and molecular regulation of lipoprotein assembly and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Beyond LDL cholesterol, a new role for PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Molecular basis of PCSK9 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Clinical aspects of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Improving antibody binding affinity and specificity for therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Dyslipidaemia: 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Adnectins: engineered target-binding protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Current prospects for RNA interference-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Locked nucleic acid oligonucleotides: the next generation of antisense agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Pharmacological strategies for lowering LDL cholesterol: statins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Lipid, blood pressure and kidney update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248414539562

21 January 2018

Identifiers

DOI

10.1177/1074248414539562

1 reference

31 August 2017

1 reference